All In Biotech

Drug Trial Radar · NCT01838681

Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Flexible-dose Long-term Study to Evaluate the Maintenance of Efficacy and Safety of 1 to 3 mg/Day of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

Last checked: Nov 19, 2026Latest source record: Aug 9, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,986 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,986

Actual

Start

Jun 2013

Primary completion

Jun 2016

Study completion Jun 2016

Sponsor

Lead sponsor
H. Lundbeck A/SIndustry
Sponsor type
Industry
Collaborators
Otsuka Pharmaceutical Co., Ltd.
First posted
Apr 24, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the long-term efficacy and safety of brexpiprazole as an adjunctive treatment to an antidepressant treatment (ADT) for adult patients with Major Depressive Disorder (MDD).

Conditions

  • Major Depressive Disorder

Interventions

  • PlaceboDrug

    Once daily, tablets, orally

  • BrexpiprazoleDrug

    1, 2, or 3 mg/day, once daily dose, tablets, orally. Uptitration in weekly steps from 1 mg/day

  • ADTDrug

    Duloxetine, escitalopram, fluoxetine, paroxetine IR, sertraline, venlafaxine XR; dosing according to label

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Full Remission During the Randomised Treatment PeriodTime frame: From randomisation to end of Period B (24 weeks)

Locations

107 sites in 16 countries. Site status is shown where the registry gives one.

  • US041

    Little Rock, Arkansas

  • US043

    Cerritos, California

  • US042

    Temecula, California

  • US053

    Flowood, Mississippi

  • US040

    Brooklyn, New York

  • US046

    Houston, Texas

  • US052

    Houston, Texas

  • US047

    Milwaukee, Wisconsin

  • BG007

    Kardzhali, Bulgaria

  • BG002

    Pazardzhik, Bulgaria

  • BG003

    Rousse, Bulgaria

  • BG001

    Sofia, Bulgaria

  • BG004

    Sofia, Bulgaria

  • BG005

    Varna, Bulgaria

  • BG006

    Varna, Bulgaria

  • CA003

    Burlington, Canada

  • CA004

    Edmonton, Alberta, Canada

  • CA001

    Kingston, Canada

  • CA002

    Montral, Canada

  • CA005

    Montreal, Canada

  • EE002

    Tallinn, Estonia

  • EE003

    Tallinn, Estonia

  • EE006

    Tallinn, Estonia

  • EE001

    Tartu, Estonia

  • EE005

    Tartu, Estonia

  • EE004

    Võru, Estonia

  • FI002

    Helsinki, Finland

  • FI003

    Helsinki, Finland

  • FI006

    Helsinki, Finland

  • FI001

    Kuopio, Finland

  • FI007

    Pori, Finland

  • FI009

    Tampere, Finland

  • DE007

    Berlin, Germany

  • DE014

    Berlin, Germany

  • DE015

    Berlin, Germany

  • DE006

    Bielefeld, Germany

  • DE010

    Bochum, Germany

  • DE012

    Gelsenkirchen, Germany

  • DE009

    Hanover, Germany

  • DE022

    Hattingen, Germany

Showing 40 of 107 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.